Physician profile
Deepthi Rao
NPI 1215167838
$1,401.70
in general payments reported to CMS, 2019-2025
23 companies · $463 in 2025
The $463 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $53.46 · 2021: $153 · 2022: $268 · 2023: $186 · 2024: $60.31 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $709.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $693.67 | 2019-2024 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $97.07 | 2019 | |
| Amgen INC. | $90.17 | 2025 | Tepezza |
| Abbvie INC. | $70.13 | 2025 | |
| Tandem Diabetes Care, INC. | $52.24 | 2019 | |
| Abbott Laboratories | $36.00 | 2023-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $27.45 | 2019-2025 | Mounjaro |
| Corcept Therapeutics | $27.40 | 2025 | Korlym |
| Actelion Pharmaceuticals US, INC. | $26.96 | 2024 | Opsumit, Uptravi |
| Mallinckrodt Hospital Products INC. | $25.83 | 2025 | Acthar |
| Beta Bionics, INC. | $24.97 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sequel Med Tech, LLC | $24.43 | 2025 | Twiist |
| Madrigal Pharmaceuticals | $24.08 | 2025 | Rezdiffra |
| Ionis Pharmaceuticals, INC. | $23.72 | 2025 | Tryngolza |
| Rhythm Pharmaceuticals, INC. | $23.66 | 2025 | Imcivree |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $22.42 | 2025 | Mycapssa |
| Organon LLC | $18.80 | 2025 | Hadlima, Renflexis |
| Kyowa Kirin, INC. | $18.25 | 2025 | |
| Medtronic Minimed, INC. | $18.04 | 2019 | |
| Xeris Pharmaceuticals, INC. | $15.97 | 2025 | Gvoke Hypopen |
| Mannkind Corporation | $14.41 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.18 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepthi Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.